The FDA proposed sweeping changes to physician labeling for prescription drugs and biologic products to provide more accurate information about using the agents during pregnancy and breastfeeding.
The Food and Drug Administration (FDA) recently proposed sweeping changes to physician labeling for prescription drugs and biologic products to provide more accurate information to both health-care professionals and their patients about using the agents during pregnancy and breastfeeding.
The hope is that by changing physician labeling, the information will trickle down to women either through package inserts and medication guides or directly through conversation.
The proposed rule would remove the letter category system now in use and replace it with a new pregnancy section on the label that would have three subsections. The first, called the "Fetal Risk Summary," would describe what is known about the effects of the drug on the fetus, including whether the information comes from human or animal studies. The second section called "Clinical Considerations" would include available information about the effects of the agent if it is used before a woman knows she is pregnant. And the third section called "Data" would describe in greater detail studies used to provide information for the "Fetal Risk Summary" section.
FDA proposes new rule to provide updated information on the use of prescription drugs and biological products during pregnancy and breast-feeding. Http:// http://www.fda.gov/bbs/topics/NEWS/2008/NEW01841.html. Accessed 5/28/08.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More